MELD score is predictive of 90-day mortality after veno-arterial extracorporeal membrane oxygenation support.

Model for End-Stage Liver Disease Veno-arterial extracorporeal membrane oxygenation acute heart failure cardiogenic shock mortality

Journal

The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 28 10 2021
medline: 15 3 2022
entrez: 27 10 2021
Statut: ppublish

Résumé

The Model for End-Stage Liver Disease (MELD) score was originally described as a marker of survival in chronic liver disease. More recently, MELD and its derivatives, MELD excluding INR (MELD-XI) and MELD with sodium (MELD-Na), have been applied more broadly as outcome predictors in heart transplant, left ventricular assist device placement, heart failure, and cardiogenic shock, with additional promising data to support the use of these scores for prediction of survival in those undergoing veno-arterial extracorporeal membrane oxygenation (VA ECMO). This study assessed the prognostic impact of MELD in patients with cardiogenic shock undergoing VA ECMO via a single-center retrospective review from January 2014 to March 2020. MELD, MELD-XI, and MELD-Na scores were calculated using laboratory values collected within 48 h of VA ECMO initiation. Multivariate Cox regression analyses determined the association between MELD scores and the primary outcome of 90-day mortality. Receiver operating characteristics (ROC) were used to estimate the discriminatory power for MELD in comparison with previously validated SAVE score. Of the 194 patients, median MELD was 20.1 (13.7-26.2), and 90-day mortality was 62.1%. There was a significant association between MELD score and mortality up to 90 days (hazard ratio (HR) = 1.945, 95% confidence interval (95% CI) = 1.244-3.041, MELD score accurately predicts long-term mortality and may be utilized as a valuable decision-making tool in patients undergoing VA ECMO.

Sections du résumé

BACKGROUND BACKGROUND
The Model for End-Stage Liver Disease (MELD) score was originally described as a marker of survival in chronic liver disease. More recently, MELD and its derivatives, MELD excluding INR (MELD-XI) and MELD with sodium (MELD-Na), have been applied more broadly as outcome predictors in heart transplant, left ventricular assist device placement, heart failure, and cardiogenic shock, with additional promising data to support the use of these scores for prediction of survival in those undergoing veno-arterial extracorporeal membrane oxygenation (VA ECMO).
METHODS METHODS
This study assessed the prognostic impact of MELD in patients with cardiogenic shock undergoing VA ECMO via a single-center retrospective review from January 2014 to March 2020. MELD, MELD-XI, and MELD-Na scores were calculated using laboratory values collected within 48 h of VA ECMO initiation. Multivariate Cox regression analyses determined the association between MELD scores and the primary outcome of 90-day mortality. Receiver operating characteristics (ROC) were used to estimate the discriminatory power for MELD in comparison with previously validated SAVE score.
RESULTS RESULTS
Of the 194 patients, median MELD was 20.1 (13.7-26.2), and 90-day mortality was 62.1%. There was a significant association between MELD score and mortality up to 90 days (hazard ratio (HR) = 1.945, 95% confidence interval (95% CI) = 1.244-3.041,
CONCLUSION CONCLUSIONS
MELD score accurately predicts long-term mortality and may be utilized as a valuable decision-making tool in patients undergoing VA ECMO.

Identifiants

pubmed: 34702105
doi: 10.1177/03913988211054865
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

404-411

Auteurs

Mohamad Karnib (M)

Division of Cardiovascular Disease, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Rebecca Haraf (R)

Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Nour Tashtish (N)

Division of Cardiovascular Disease, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Erica Zanath (E)

Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Tarek Elshazly (T)

Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Raul Angel Garcia (RA)

Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, MO, USA.

Scott Billings (S)

Enterprise Data Services Department, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Michael Fetros (M)

Enterprise Data Services Department, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Allison Bradigan (A)

Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Michael Zacharias (M)

Division of Cardiovascular Disease, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Yasir Abu-Omar (Y)

Division of Cardiovascular Surgery, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Yakov Elgudin (Y)

Division of Cardiovascular Surgery, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Marc Pelletier (M)

Division of Cardiovascular Surgery, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Sadeer Al-Kindi (S)

Division of Cardiovascular Disease, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Francis Lytle (F)

Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Chantal ElAmm (C)

Division of Cardiovascular Disease, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH